





itioner's Docket No.

49979 (71965)

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Y. Taya et al.

Serial No.:

09/618,424

Filed: For:

July 18, 2000

Group No.: Examiner:

1641

K. Padmanabhan

METHOD FOR DETECTING ACETYLTRANSFERASE AND

DEACETYLASE ACTIVITIES AND METHOD FOR SCREENING

INHIBITORS OR ENHANCERS OF THESE ENZYMES.

Box AF **Assistant Commissioner for Patents** Washington, D.C. 20231

RESPONSE UNDER 37 C.F.R. 1.116 EXPEDITED PROCEDURE **EXAMINING GROUP** 1641

NOTE: To take advantage of the expedited procedure the envelope in which this paper is mailed must be addressed as shown and must also be marked "Box AF" in the lower left hand corner. Alternatively, this paper can be hand carried to the particular Examining Group or other area of the Office in which the application is pending, in which case any envelope in which this paper is placed must be marked as in the bold type box above. Notice of Sept. 20, 1985 (1059 O.G. 19-20).

#### CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10\*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

# **MAILING**

×	deposited with the United States Postal Service in Washington, D.C. 20231.	dressed to the Assistant Commis	ssioner for Patents,				
	37 C.F.R. 1.8(a)		37 C.F.R. 1.10*				
X	with sufficient postage as first class mail.		as "Express Mail Post Office to Address"				
			Mailing Label No	(mandatory)			
	TRA	NSMISSION					
	transmitted by facsimile to the Patent and Trademark Office.						
	4	V					
		Signa	iture				
Date: _	October 3, 2002	Pet	er F. Corless				
		(type	or print name of person certifyir	ıg)			

\*WARNING:

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).

"Since the filing of correspondence under  $\S$  1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Amendment or Response After Final Rejection—Transmittal—page 1 of 4)

# AMENDMENT OR RESPONSE AFTER FINAL REJECTION—TRANSMITTAL

1. NOTE:	Respons Period ( Office A the date	se to Final Rejection—Avoidi (SSP) is set for response to a lction, If filed within two mo	amendment after final rejection (37 C.F.R. 1.116) for this application. oiding Extension Fees "In patent applications wherein a three month Shortened Statutory to a Final Rejection, the response would best be filed within two months of the date of the months, any Advisory Action mailed after the SSP expires will reset the SSP to expire on for extension fee purposes, but never more than six months from the date of the Final 90 (1122 O.G. 571 to 591).				
			STATUS				
2.	Applic	ant is					
	[X] [ ]	a small entity. A state other than a small ent					
			EXTENSION OF TERM				
NOTE:	As to a 34-35) s		led in response to a final office action, the i	Notice of December 10, 1985 (1061 O.G.			
		and/or entry of a Notice of shortened statutory period	been filed after a Final Office Action, an ext of Appeal or filing and/or entry of an addi unless the timely-filed response placed the d al has been filed within the shortened statuto	tional amendment after expiration of the application in condition for allowance. Of			
3.	(comp	lete (a) or (b), as applic	able)				
	(a)		citions for an extension of time under R. 1.17(a)(1)-(4)) for the total numb				
		Extension	Fee for other than	Fee for			
		(months)	small entity	small entity			
	[]	one month	\$110.00	\$55.00			
	[ ]	two months	\$400.00	\$200.00			
	ΪĪ	three months	\$920.00	\$460.00			
	[ ]	four months	\$1,440.00	\$720.00			
			Fee: \$				
If addi	tional ex	ctension of time is requi	red, please consider this a petition th	erefor.			
		(check a	nd complete the next item, if applica	ble)			
	[]	An extension for months has already been secured and the fee paid therefor of \$ is deducted from the total fee due for the total months of extension now requested.					
		Extension fee	due with this request \$				

OR

(b) [X] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

### **FEE FOR CLAIMS**

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

			SMALL ENTITY		OTHER THAN A SMALL ENTITY				
	Claims								
	Remainin	g	Highest No.						
	After		Previously	Present		Addit.			Addit.
	Amendme	ent	Paid For	Extra	Rate	Fee	OR	Rate	Fee
Total	*	Minus	**	=	x \$11 =	\$		x \$22 =	\$
Indep.	*	Minus	***	=	x \$41 =	\$		x \$82 =	\$
[ ] Firs	t Presentati	on of Mu	ltiple Depender	nt Claim	+ \$135 =	= \$		+ \$270 =	\$
					Total		OR	Total	
					Addit. Fee	\$		Addit. Fee	\$

- \* If the entry in Col. 1 is less than the entry in Col. 2, write "O" in Col. 3,
- \*\* If the "Highest No. Previously Paid For" IN THIS SPACE is less than 20, enter "20".
- \*\*\* If the "Highest No. Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest No. Previously Paid For" (Total or Indep.) is the highest number found in the appropriate box in Col. 1 of a prior amendment or the number of claims originally filed.

**WARNING:** See 37 C.F.R. § 1.116. (complete (c) or (d), as applicable) (c) [X] No additional fee is required. OR (d) [] Total additional fee required is \$ **FEE PAYMENT** 5. [] Attached is a check in the sum of \$\_\_ [] Charge Account No. \_\_\_\_\_ the sum of \$ A duplicate of this transmittal is attached.

#### FEE DEFICIENCY

NOTE: Where there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO Finance Branch in order to apply these charges prior to action on the case. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, (1065 O.G. 31-33).

6. If any additional extension and/or fee is required, charge Account No. 04-1105.

### AND/OR

[X] If any additional fee for claims is required, charge Account No. \_\_\_\_04-1105

SIGNATURE OF PRACTITIONER

Reg. No. 33,860 Peter F. Corless

(type or print name of practitioner)

**EDWARDS & ANGELL, LLP** 

P.O. Box 9169

P.O. Address

Boston, Massachusetts 02209

Tel. No. (617) 439-4444

Customer No. 21874



Docket No. 4

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Y. Taya et al.

U.S.S.N.

09/618,424

EXAMINER: K. Padmanabhan

FILED:

July 18, 2000

ART UNIT: 1641

FOR:

METHOD FOR DETECTING ACETYLTRANSFERASE AND

DEACETYLASE ACTIVITIES AND METHOD FOR SCREENING

INHIBITORS OR ENHANCERS OF THESE ENZYMES

THE HONORABLE COMMISSIONER OF PATENTS AND TRADEMARKS WASHINGTON, DC 20231

SIR:

### AMENDMENT AFTER FINAL REJECTION

Applicants are in receipt of the Final Office Action dated July 3, 2002. Please amend the application as follows.

### IN THE CLAIMS

- 16. (amended) A method for screening a compound that inhibits or enhances activity of an acetyltransferase to catalyze a reaction that transfer an acetyl group from one substrate to another, the method comprising:
- (a) contacting the acetyltransferase with a peptide substrate in a presence of a test compound,
- detecting an amount of an acetylated peptide substrate using an anti-acetylated (b) peptide antibody, wherein the anti-acetylated peptide antibody recognizes only an acetylated form of the peptide substrate and does not recognize the peptide substrate in its unacetylated form,
- (c) comparing the amount of the acetylated peptide substrate detected in step (b) with a control amount defined as an amount of an acetylated peptide substrate detected in an absence of the test compound, and
  - selecting the compound associated with an increase or decrease in the amount of (d)